

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



30 December 2020

UBI's Canadian subsidiary signs deal with Bayer AG

Universal Biosensors, Inc. (ASX:UBI) is pleased to announce that its Canadian subsidiary, Hemostasis Reference Laboratory Inc (HRL), has entered into an agreement with Bayer AG of Germany (Bayer) for the provision of certain services relating to the performance of laboratory analysis of biological samples. The services are to be provided over an agreed period of time and will generate CAD \$1.3 million of additional revenue for HRL.

John Sharman, CEO of UBI commented "HRL is our laboratory service business in Canada and is an important asset in our blood testing business. We are looking to grow HRL and expand the client base over time. The contract with Bayer is a significant first step and we expect to be in a position to announce additional contracts with other customers over the course of the next six months."

End

Enquiries:
John Sharman
Chief Executive Officer
+61 (0) 414 440 680

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.



Universal Biosensors

About Universal Biosensors

For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), food and drink and agriculture.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.